ArticlePloS one2021
Blood biomarker discovery for autism spectrum disorder: A proteomic analysis.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Biomarkers and pathways in autism spectrum disorder: An individual meta-analysis based on proteomic and metabolomic data.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- Autologous cord bloodWorld journal of clinical pediatrics · 2025Trial
- Altered Gut Microbiota and Short-chain Fatty Acids in Chinese Children with Constipated Autism Spectrum Disorder.Scientific reports · 2023Trial
- Validation of plasma protein glycation and oxidation biomarkers for the diagnosis of autism.Molecular psychiatry · 2024Article
- Article
- Retraction: Blood biomarker discovery for Autism Spectrum Disorder: A proteomic analysis.PloS one · 2024Article
- A new diagnostic autism spectrum disorder (DASD) strategy using ensemble diagnosis methodology based on blood tests.Health information science and systems · 2023Article
- Characterization of Primary Muscle Tension Dysphonia Using Acoustic and Aerodynamic Voice Metrics.Journal of voice : official journal of the Voice Foundation · 2023Article
- Article
- Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD).Life (Basel, Switzerland) · 2023Article
- Blood Proteomics Analysis Reveals Potential Biomarkers and Convergent Dysregulated Pathways in Autism Spectrum Disorder: A Pilot Study.International journal of molecular sciences · 2023Article
- A predictive ensemble classifier for the gene expression diagnosis of ASD at ages 1 to 4 years.Molecular psychiatry · 2023Article
- Inflammation and the Potential Implication of Macrophage-Microglia Polarization in Human ASD: An Overview.International journal of molecular sciences · 2023Review
- High-throughput autoantibody screening identifies differentially abundant autoantibodies in autism spectrum disorder.Frontiers in molecular neuroscience · 2023Article
- Towards the Development of a Diagnostic Test for Autism Spectrum Disorder: Big Data Meets Metabolomics.The Canadian journal of chemical engineering · 2023Article
- Autism spectrum disorder diagnosis using a new panel of immune- and inflammatory-related serum biomarkers: A case-control multicenter study.Frontiers in pediatrics · 2023Article
- Placental proteins with predicted roles in fetal development decrease in premature infants.Pediatric research · 2022Article
- A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.Experimental brain research · 2022Review
- A Combined Proteomics and Metabolomics Profiling to Investigate the Genetic Heterogeneity of Autistic Children.Molecular neurobiology · 2022Article
- A Deep Neural Network-Based Model for Screening Autism Spectrum Disorder Using the Quantitative Checklist for Autism in Toddlers (QCHAT).Journal of autism and developmental disorders · 2022Article
Corrections and comments
- Retraction · 2024-03-28Author Unresponsive · Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Error in Analyses · Error in Methods · Investigation by Journal/Publisher · Results Not Reproducible · Unreliable Data · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) ·
- Retracted
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests, or activities. Given the lack of specific pharmacological therapy for ASD and the clinical heterogeneity of the disorder, current biomarker research efforts are geared mainly toward identifying markers for determining ASD risk or for assisting with a diagnosis. A wide range of putative biological markers for ASD is currently being investigated. Proteomic analyses indicate that the levels of many proteins in plasma/serum are altered in ASD, suggesting that a panel of proteins may provide a blood biomarker for ASD. Serum samples from 76 boys with ASD and 78 typically developing (TD) boys, 18 months-8 years of age, were analyzed to identify possible early biological markers for ASD. Proteomic analysis of serum was performed using SomaLogic's SOMAScanTM assay 1.3K platform. A total of 1,125 proteins were analyzed. There were 86 downregulated proteins and 52 upregulated proteins in ASD (FDR < 0.05). Combining three different algorithms, we found a panel of 9 proteins that identified ASD with an area under the curve (AUC) = 0.8599±0.0640, with specificity and sensitivity of 0.8217±0.1178 and 0.835±0.1176, respectively. All 9 proteins were significantly different in ASD compared with TD boys, and were significantly correlated with ASD severity as measured by ADOS total scores. Using machine learning methods, a panel of serum proteins was identified that may be useful as a blood biomarker for ASD in boys. Further verification of the protein biomarker panel with independent test sets is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.